Director, Nanospectra Biosciences in Houston, TX. Nanospectra is a private company founded in 2002. The company has an exclusive license from Rice University to eleven issued US patents related to nanoshells and related commercial uses of these and other nanoparticles. While there are numerous therapeutic, diagnostic, and industrial commercial applications, Nanospectra is focused on the development of AuroLase® Therapy utilizing AuroShell® Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors.

Sognef Inc. has developed technology for massively multiplexed analysis of low abundance analytes in clinical and non-clinical liquid samples with a rapid, highly accurate and simple to use reagent-free platform. The company will apply this technology to the analysis of clinical samples for a wide range of diseases, non-clinical analysis of chemicals and for research studies. We are currently seeking partners for all potential applications.

Exploiting 30 years of deep experience in the cancer diagnostics, device and therapeutics markets, I have served as executive strategic consultant for companies developing and marketing novel products with high clinical value for cancer patients. Our capabilities include market and business research, go-to-market strategy development, technical evaluation, project management, technology acquisition and outlicensing, market development, KOL development and expert analysis of business opportunities in the cancer marketpace. I am currently serving as consulting COO to a start-up company developing a unique biomarker for monitoring and prognosis of multiple myeloma and other B-Cell related cancers. Recently I served as consulting Executive VP of Marketing for Exosome Diagnostics, strategic marketing consultant to Myriad Diagnostics, international market strategy consultant for IRIS International, molecular diagnostics strategy consultant for GTx Pharmaceuticals, business development consultant for NovioGendix, a cancer specialty diagnostics laboratory in The Netherlands and as US strategy consultant for Advanced Medical Diagnostics, (www.HistoScanning.com) in Waterloo, Belgium.

SNP Bio was founded to commercialize clinically validated genetic tests to determine patients risk of developing specific cancers and other serious diseases. The company’s initial product, the PGS-33™ prostate cancer Genetic Risk Score (GRS), is the first advanced genetic test to predict the lifetime risk of individuals developing prostate cancer. The test supplements family history in the decision to offer active, biomarker-based screening. PGS-33 draws upon data from over 87,000 patients, and has been directly validated in over 7,000 patients from the most important prostate cancer detection studies. This Screen Smarter™ approach will allow determination of which men need risk-adapted screening, potentially leading to lower healthcare costs and reduced morbidity. SNP Bio, a privately held company, is based in San Diego, California. SNP Bio will be commercializing the PGS-33 genetic test to determine a man's personalized lifetime risk of developing prostate cancer. Validated in studies on over 20,000 patients published in top journals, the test will help men know if they should be screened for prostate cancer. Using my broad connections in the prostate cancer community, I created awareness of the company with leading key opinion leaders and developed the company business plan that resulted in commitment for initial seed-round investment.

I was hired to build a cancer diagnostics business utilizing Metbaolon's core metabolomics platform supplemented by complementary technologies. The position was eliminated after 4 months due to a change in corporate strategy.

Originally hired as consultant to evaluate company's novel prostate cancer diagnostic technology. Hired full-time to identify commercialization partner and lead negotiation team to establish profitable relationship. With this accomplished, managed the relationship while helping to raise financing for the company and giuding corporate strategy. Established market launch strategy for the company's novel colorectal cancer molecular diagnostic test and associated CLIA laboratory.

With three other serial entrepreneurs, directed the start-up of this clinical trial data mining enterprise, including development of business strategy, attracting capital investment,business development and technical staffing. Efforts to develop the company were ceased due to technical issues and financing environment.

ATI was developing an implantable device for the treatment of prostate cancer. I was primarily responsible for managing all marketing, product development and clinical activities. This included establishing market awareness with Key Opinion Leaders, managing key supplier relationships and recruiting initial clinical trial sites.

This was a continuation of my responsibilities after the acquisition of Hybritech by Beckman. I was responsible for creating strategic plans for Cancer and Osteoporosis diagnostic businesses as well as analysis of the overall strategic direction for Hybritech.

In Marketing: Launched and built worldwide market for first commercial PSA assay, Directed team managing in-vitro cancer diagnostics franchise. Built virtual Medical Affairs group comprised of world-recognized experts. Peak sales exceeded $100MM for PSA alone. I was also the primary marketing liaison for corporate alliances with Centocor and Baxter/DADE.In R&D: As Director, Project Management Directed two dedicated teams of scientists and professionals from all departments to develop and launch novel cancer products. One project resulted in the international launch of a new prostate cancer test in nine months from concept.In General Management: As Director of Strategic Planning developed long-term strategic plans for cancer and osteoporosis businesses.In Sales: Directed team of nine professional sales representatives to grow sales of broad product line.